| Author/Editor | Srikanthan, Amirrtha; Vera-Badillo, Francisco Emilio; Ethier, Josee-Lyne; Goldstein, Robyn; Templeton, Arnoud J.; Ocaña, Alberto; Šeruga, Boštjan; Amir, Eitan | |
| Title | Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies | |
| Type | članek | |
| Vol. and No. | Letnik 43, št. 2 | |
| Publication year | 2016 | |
| Volume | str. 67-73 | |
| ISSN | 0305-7372 - Cancer treatment reviews | |
| Language | eng | |
| Abstract | Eligibility criteria in randomized controlled trials (RCTs) reduce inter-patient heterogeneity, but may reduce generalizability of results. Here, we explore temporal changes in eligibility criteria of practice-changing RCTs for systemic cancer therapies and in the proportion of patients excluded from these trials after application of eligibility criteria. Methods: Anelectronic searchidentifiedpractice-changingRCTspublishedinsixmajor journalsbetweenJuly 2010 and December 2012. Trial protocols were identified through journalwebsites and communicationwith authors or study sponsors. Eligibility criteriawere extracted fromprotocols. The number of patients excluded after application of eligibility criteria was extracted from the CONSORT diagrams and text of publications. Changes in eligibility criteria over time were assessed by logistic regression and meta-regressionwas carried out toevaluate theimpact ofyearofprotocol onthe proportionofpatientswhowere excludedafter screening. Results: Eighty-six protocols written between 1987 and 2012 were included. Over time, there has been an increasing frequency of exclusion of patientswith prior cerebrovascular events (OR 1.34, p = 0.003), coagulation/ bleeding disorders (OR 1.34, p = 0.006), prior gastrointestinal bleeding (OR 1.33, p = 0.01), cardiac comorbidities (OR 1.24, p = 0.004) and exclusion based on concurrent medication (OR 1.19, p = 0.01). There has been a decrease in upper age limit usage (OR 0.83, p = 0.01) and leukopenia (OR 0.83, p = 0.009). The proportion of patients excluded from trials has increased from 9% prior to 2000 to 18% after 2010 (p-value for trend <0.001). Conclusions: RCTs have become less representative of cancer patients treated in routine practice with increased use of organ-specific and co-morbidity-based exclusion criteria. | |
| Keywords | randomizirane klinične raziskave evalvacija vključitveni kriteriji sistemska terapija randomized controlled trials eligibility criteria systemic therapy trial evaluation |